Nutriflex Omega Special Injection
Glucose Monohydrate 39.6g · Monobasic Sodium Phosphate Hydrate 0.624g +26 more
Injections · Prescription medication · Combination
B. Braun Korea Co., Ltd.
MFDS item code 201602415 · Approved 2016.04.28
This product's status changed to Approval withdrawn on 2024.10.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of deficiencies in nutrients (essential fatty acids, amino acids, etc.), fluids, and electrolytes
This medication is used to supply necessary fluids, essential fatty acids (omega-3 and omega-6), amino acids, electrolytes, and calories intravenously to patients who are unable to consume nutrients orally or through the gastrointestinal tract or when intake is insufficient.
Administer via a central vein. Determine the infusion rate by considering the total dose, the characteristics of the final admixture to be infused, the daily dose, and the infusion duration. Usually, gradually increase the dose during the first 30 minutes of infusion until the appropriate dose is reached. There is no fixed limit to the treatment duration; however, when administered long term, appropriate vitamins, trace elements, and minerals should be provided. Do not exceed a maximum infusion rate of 1.7mL/kg/hour (equivalent to 0.1g/kg/hour of amino acids, 0.24g/kg/hour of glucose, and 0.07g/kg/hour of fat). For a patient weighing 70kg, this corresponds to an infusion rate of 119mL/hour (delivering 6.8g of amino acids, 17.1g of glucose, and 4.8g of fat per hour). Determine the dose according to the patient's condition, energy expenditure, and metabolic requirements. ㆍ Determine the dose according to the patient's nutritional status and degree of catabolism, but do not exceed 40kcal/kg per day. An exception may be made in special cases, such as patients with burns. ㆍ Maximum daily dose: 35mL per kg of the patient's body weight (equivalent to 2.0g of amino acids, 5.04g of glucose, and 1.4g of fat per kg of body weight).
This drug must be used strictly according to a physician's instructions. If symptoms of anaphylaxis such as fever, tremors, rash, or difficulty breathing occur, administration should be stopped immediately. When used with intravenous calcium-containing preparations, it must not be mixed with ceftriaxone, and the same infusion device should not be used simultaneously. If the same infusion line is to be used for continuous infusion, it should be thoroughly flushed with appropriate solution before and after administration. Caution is needed because the lipid components of this drug can increase the level of free fatty acids in the blood of premature or underweight infants. This drug should particularly not be administered to premature infants under 2 years, neonates and infants, patients with certain allergic reactions, patients with severe renal failure or liver disease, and patients with amino acid metabolism disorders. It should be used cautiously in patients with specific diseases such as renal failure, pancreatitis, liver dysfunction, heart failure, pulmonary failure, diabetes, and blood triglyceride levels and electrolyte status should be monitored frequently. During administration, adverse reactions such as mild fever, chills, nausea, vomiting, respiratory distress, headache, blood pressure changes, skin rashes may occur, and administration should be stopped in severe cases. Additionally, this medication may affect blood coagulation, so patients with coagulation disorders or vitamin K deficiency should exercise caution. Before administration, the patient's hydration status, electrolyte levels, and acid-base balance must be checked and adjusted, and blood glucose and lipid levels should be regularly monitored and adjusted or stopped if abnormalities arise. This drug may interact with other medications, so if there are any concomitant medications, it is essential to consult with a physician or pharmacist. Safety in pregnant or breastfeeding women has not been established, thus benefits and risks should be carefully weighed and considered for use if necessary. Post-administration, it is advisable to consult with healthcare personnel regarding the timing and methods of blood tests, as this medication can affect test results. In case of overdose, serious adverse reactions such as acidosis, hypervolemia, hyperglycemia, liver dysfunction may occur, and administration should be stopped immediately and appropriate interventions should be undertaken. Finally, this medication should only be used after verifying the integrity of the packaging, discoloration of the solution, and contamination with foreign substances, and after opening, it should be administered promptly and unused portions should not be reused. During storage, it should be kept in a sealed container to prevent exposure to air and care must be taken to avoid freezing. The appropriate storage temperature is between 1 degree and 25 degrees.
Mild increase in body temperature, feeling of fever, chilliness, shivering, loss of appetite, nausea, vomiting, difficulty breathing, headache, back pain, bone pain, chest pain, lower back pain, decreased blood pressure, increased blood pressure, hypotension, tension, hypersensitivity reaction, anaphylactoid reaction, skin rash, hypercoagulation, allergic reaction, anaphylaxis, skin rash, laryngeal edema, oral edema, facial edema, hyperlipidemia, hyperglycemia, metabolic acidosis, ketoacidosis, drowsiness, tension, erythema, flushing, cyanosis, nausea, decreased appetite, erythema, obesity, redness, increase in body temperature, sweating, chest pain, back pain, fever, abdominal pain, fatigue, hepatomegaly, splenomegaly, liver function abnormalities, anemia, decrease in platelet count, decrease in white blood cell count, hematological pathological predisposition, bleeding, degradation of coagulation components, decrease in coagulation components
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to avoid contact with air and should not be allowed to freeze. The optimal storage temperature is between 1 degree and 25 degrees.
A parenteral emulsion injection containing three separate compartments: a lipid phase of a white liquid in a transparent container and a clear dextrose and amino acid liquid phase that is colorless or pale yellow.
625 mL/bag, 1,250 mL/bag, 1,875 mL/bag, 2,500 mL/bag
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Glucose Monohydrate 39.6g · Monobasic Sodium Phosphate Hydrate 0.624g +26 more
Injections · Prescription medication · Combination
B. Braun Korea Co., Ltd.
Glucose Monohydrate 33g · Monobasic Sodium Phosphate Hydrate 0.468g +26 more
Injections · Prescription medication · Combination
B.Braun Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.